The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback